- Pre-clinical Development
- Clinical Development
- Transbuccal Insulin
- Glucagon-like-peptide (GLP-1)
- Insulin/GLP-1 Combination
- Diabetes Immunotherapy
- Tumor Vaccines
With its partner Monosol Rx, Midatech’s most advanced programme takes advantage of the fact that binding a peptide hormone to a gold nanoparticle (GNP) enables the needle-free delivery of insulin across the mucosa of the cheek. A Phase II clinical study is planned to start in 2014.
Midatech has successfully bound glucagon-like-peptide [GLP-1] to GNPs for the treatment of Type 2 diabetes mellitus. The company has commenced pre-clinical research in this area and has generated promising early stage results.
A combination treatment in which insulin and GLP-1 are delivered on the same GNPs has also been developed and showed positive results in pre-clinical studies.
As part of a €6 million EU Framework 7 consortium grant, Midatech is developing a therapeutic vaccine using its GNP technology to inhibit the autoimmune destruction of pancreatic β-cells. The project was initiated in September 2012.
This project focuses on the development of GNPs which include folic acid (FA) and a platinum cytotoxic compound to specifically target ovarian cancer cells and is supported by a Spanish CDTI-grant.
Having demonstrated the specific migration of GNPs to the brain through the blood-brain-barrier, Midatech is optimizing nanoparticles combined with chemotherapeutic agents that will allow a new generation of therapeutic options for diseases such as glioblastoma.
Midatech has developed GNPs to specifically target the liver. Studies are currently underway to evaluate structure activity relationships with a number of payloads including doxorubicin, docetaxel and camptothecin.
Midatech is actively pursuing a therapeutic vaccine for non-small cell lung cancer based on its GNP technology. Studies were started in 2010 linking tumour-specific antigens to GNPs and investigating their potential to induce specific cytotoxic T-cell responses.